Loading…
DIA Europe 2019 has ended
View analytic
Tuesday, February 5 • 14:00 - 15:15
#DMD3: Patient Engagement as a Strategic Imperative in Therapeutic Innovation

Sign up or log in to save this to your schedule and see who's attending!

Tweet Share
Component Type: Session

Patient engagement remains very much in vogue, but does it really make a difference? This session will look at why patient engagement matters to different stakeholders in the value chain of medicines. We will explore patient engagement strategies within various institutions, organisations and companies - and the kind of buy-in needed from different stakeholders (patient organisations, industry, regulators, policy makers, HCPs) involved in making patient engagement happen across the entire life cycle. We will look candidly at some of the challenges of patient engagement and if we are where we need to be as we move towards the next decade of the 21st century. • A Brief History – The roots of patient engagement • Key Pillars of the IMI Patient Engagement Strategy • Prioritising Patient Engagement at the EMA and Looking to the Future • Transforming a Major Pharma towards Patient Engagement

Chair

Nicola Bedlington

Speaker

Panel Discussion
Dimitrios Athanasiou, MBA

Panel Discussion
Pierre Meulien, PhD

Panel Discussion
Guido Rasi, MD


Speakers
avatar for Dimitrios Athanasiou

Dimitrios Athanasiou

Patient Advocate, WORLD DUCHENNE ORGANIZATION (WDO) , MDA HELLAS
Dimitrios Athanasiou is a PDCO member representing EURORDIS. He holds a BA and an MBA in Financial Management He attended Eurordis Summer School and European Patient Academy (EUPATI) acquiring basic biotech and regulatory knowledge. As a full time patient advocate in DMD, he is a... Read More →
avatar for Nicola Bedlington

Nicola Bedlington

Secretary General, European Patient's Forum
Nicola Bedlington was first Executive Director of the European Patients’ Forum (EUPATI), which she continues to serve as its Secretary General, and is co-founder of Patients Access Partnership (PACT). She previously provided leadership to the Swiss government’s Environment and... Read More →
avatar for Pierre Meulien

Pierre Meulien

Executive Director, Innovative Medicines Initiative (IMI)
Pierre Meulien is executive director of the Innovative Medicines Initiative (IMI), a €5 billion public-private partnership between the European Union and the European pharmaceutical industry. At IMI, he is responsible for the overall management of the program, which works to improve... Read More →
avatar for Guido Rasi

Guido Rasi

Executive Director, European Medicines Agency (EMA)
Prof Guido Rasi began his second term as Executive Director of EMA on 16 November 2015. From November 2014 to mid-November 2015, he served as EMA’s Principal Adviser in Charge of Strategy. From November 2011 to November 2014 he was the Executive Director of the EMA and a member... Read More →

Tuesday February 5, 2019 14:00 - 15:15
E1 Austria Center Vienna Bruno-Kreisky-Platz 1 1220 Vienna Austria
  DIAmond Sessions, Session
  • Featured Topics Patient Engagement
  • Tags Session